Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on Sep 11, 2014 11:50am

125 Views

Post# 22927123

RE:RE:RE:RE:RE:Zenith vs RVX

Hi Jkj.

Interesting...thanks. They're using it to fund Phase 2b ixCELL-DCM clinical trial of ixmyelocel-T. So they are fairly far along in the development.

While Zenith seems to be in the early stages of trials their epi-genetic platforms have been developed over a 14 year period as RVX developed. So IMO they should be fairly advanced and there should be no barriers to an early stage IPO if the Julie can package up and sell the benefits to the market. Hope she does it soon.
Cheers
toinv

Bullboard Posts

2024, a breakthrough year for silver